Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment [1];Tratamiento a medio y largo plazo con infliximab y metotrexato en uveítis posteriores y/o crónicas rebeldes al tratamiento convencional

Medicina Clinica

Volumn 126, Issue 1, 2006, Pages 34-35

  Cobo Ibáñez, Tatiana ^a   Muñoz Fernández, Santiago ^a   Hidalgo Barrero, Ventura ^a   Martín Mola, Emilio ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN A; INFLIXIMAB; METHOTREXATE; PREDNISONE;

DRUG EFFICACY; HUMAN; LETTER; MEDICAL LITERATURE; UVEITIS;

EID: 32844455285     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083329     Document Type: Article

References (10)

1. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218:223-36.
2. Nakamura S, Yamakawa T, Sugita M, Kijima M, Ishioka M, Tanaka S, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoinmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35:3884-9.
3. Brito BE, O'Rourke LM, Pan Y, Anglin J, Planck SR, Rosenbaum JT. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci. 1999;40:2583-9.
4. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003; 110:1449-53.
5. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404-6.
6. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8.
7. Rodríguez-Valverde V, Álvaro-Gracia Álvaro JM, Andreu Sánchez JL, Battle Gualda E, Tornero Molina, en representación de los miembros del Panel. Segunda actualización del consenso de la Sociedad Española de Reumatología sobre la terapia biológica en la artritis reumatoíde. Rev Esp Reumatol. 2004;31:394-401.
8. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of uveitis Study. Ophthalmology. 2004;111:491-500.
9. Benítez del Castillo JM, Martínez de la Casa JM, Pato Cour E, Méndez Fernández R, López Abad C, Matilla M, et al. Long-term tratment of refractory posterior uveitis wih anti-TNFα [serie en internet] (infliximab). Eye. 2005;19:841-5.
10. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly mehotrexate in rheumatoid artritis. Arthritis Rheum. 1998;41:1552-63.